Compare Tango Therapeutics Inc. (TNGX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Veritone Inc — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Veritone Inc trades at $0.53 (market cap $59.95M). The key difference: Tango Therapeutics Inc. is far larger — about 62.6× Veritone Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Veritone Inc for 13 Days on average.
| TNGX | VERI | |
|---|---|---|
Market Cap | $3.75B | $59.95M |
Volume | 9,619,106 | 2,880,267 |
Sector | Health | Technology |
52-Week High | $32.90 | $8.39 |
52-Week Low | $7.50 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $2.77B | $95.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Veritone (VERI) trades at $0.59, down 2.64% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative cash flow from operations. Recent news includes a $15M equity offering and partnerships like the ATP Media deal, while facing a securities class action investigation.
The outlook remains challenged by persistent losses and cash burn, though analyst consensus is a Buy with a $3.75 price target. Key risks include execution on cost reductions, competitive pressures in AI, and legal overhangs. Upside hinges on revenue acceleration and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
